

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number  
**WO 02/03805 A1**

- (51) International Patent Classification<sup>7</sup>: **A21D 8/04**, (74) Common Representative: **NOVOZYMES A/S**; Patents, A23L 1/03 Krogshøjvej 36, DK-2880 Bagsværd (DK).
- (21) International Application Number: **PCT/DK01/00472**
- (22) International Filing Date: **6 July 2001 (06.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
PA 2000 01054 **6 July 2000 (06.07.2000)** **DK**  
60/217,051 **10 July 2000 (10.07.2000)** **US**
- (71) Applicant (*for all designated States except US*): **NOVOZYMES A/S** [DK/DK]; Krogshøjvej 36, DK-2880 Bagsværd (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **BUDOLFSEN, Gitte** [DK/DK]; Drosselvej 53M, DK-2000 Frederiksberg (DK). **CHRISTENSEN, Luise** [DK/DK]; Sommerstedgade 11, 2th, DK-1718 København V (DK). **FORMAN, Todd** [US/US]; 3409 Ribcowski Court, Raleigh, NC 27616 (US). **SPENDLER, Tina** [DK/DK]; Hjortespringparken 40, DK-2730 Herlev (DK).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *with international search report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 02/03805 A1**

(54) Title: METHOD OF PREPARING A DOUGH OR A BAKED PRODUCT MADE FROM A DOUGH, WITH ADDITION OF LIPOLYTIC ENZYMES

(57) Abstract: The addition to dough of a combination of two lipolytic enzymes with different substrate specificities produces a synergistic effect on the dough or on a baked product made from the dough, particularly a larger loaf volume of the baked product and/or a better shape retention during baking.

METHOD OF PREPARING A DOUGH OR A BAKED PRODUCT MADE FROM A DOUGH, WITH ADDITION  
OF LIPOLYTIC ENZYMES

### TECHNICAL FIELD

The present invention relates to methods of preparing a dough or a baked product made from dough by use of lipolytic enzymes, and to compositions for use  
5 therein.

### BACKGROUND

WO 94/04035, EP 109244, EP 585988, WO 98/26057, WO 98/45453, WO 99/53769, WO 00/32758 and EP 575133 describe the addition of various lipolytic enzymes to dough in the preparation of bread, e.g. enzymes with activities such as  
10 triacylglycerol lipase, phospholipase and galactolipase.

### SUMMARY OF THE INVENTION

The inventors have found that the addition to dough of a combination of two lipolytic enzymes with different substrate specificities produces a synergistic effect on the dough or on a baked product made from the dough, particularly a larger loaf  
15 volume of the baked product and/or a better shape retention during baking.

Accordingly, the invention provides a method of preparing a dough or a baked product made from dough, comprising adding a combination of two lipolytic enzymes to the dough. The invention also provides a composition comprising a combination of two lipolytic enzymes.

20 The combination may comprise at least two lipolytic enzymes selected from the group consisting of galactolipase, phospholipase and triacylglycerol lipase. Thus, the combination may comprise a galactolipase + a phospholipase, a phospholipase + a triacylglycerol lipase or a triacylglycerol lipase + a galactolipase.

### DETAILED DESCRIPTION OF THE INVENTION

#### 25 Lipolytic enzyme

The invention uses a combination of lipolytic enzymes, i.e. enzymes which are capable of hydrolyzing carboxylic ester bonds to release carboxylate (EC 3.1.1). The enzyme combination includes at least two of the following three: a galactolipase, a phospholipase and a triacylglycerol lipase, i.e. enzymes predominantly having activity  
30 for a galactolipids, a phospholipid, and a triglyceride, respectively. The activities may be determined by any suitable method, e.g. by assays known in the art or described later in this specification.

- Galactolipase activity (EC 3.1.1.26), i.e. hydrolytic activity on carboxylic ester bonds in galactolipids such as DGDG (digalactosyl diglyceride). The

galactolipase activity (digalactosyl diglyceride hydrolyzing activity or DGDGase activity) may be determined, e.g., by the plate assay in this specification or by the monolayer assay 1 or 2 in WO 2000/32758.

- 5     ▪ Phospholipase activity (A1 or A2, EC 3.1.1.32 or 3.1.1.4), i.e. hydrolytic activity towards one or both carboxylic ester bonds in phospholipids such as lecithin. The phospholipase activity may be determined by the plate assay in this specification or by an assay WO 2000/32758, e.g. the PHLU, LEU, monolayer or plate assay 1 or 2.
- 10    ▪ Triacylglycerol lipase activity (EC 3.1.1.3), i.e. hydrolytic activity for carboxylic ester bonds in triglycerides, e.g. 1,3-specific activity, particularly on long-chain triglycerides such as olive oil. The activity on long-chain triglycerides (olive oil) and short-chain triglycerides (tributyrin) may be determined by the SLU and LU methods (described in WO 00/32758), respectively, or by the plate assay described in this specification. The enzyme may have a substrate specificity for  
15    hydrolyzing long-chain fatty acyl groups rather than short-chain groups, expressed e.g. as a high ratio of activities on olive oil and tributyrin, e.g. the ratio SLU/LU. Favorably, this may reduce the development of off-odor in dough containing milk lipids such as butter fat. Suitably, this ratio may be above 3.

Each lipolytic enzyme may have a narrow specificity with activity for one of the  
20 three substrates and little or no activity for the other two, or it may have a broader specificity with predominant activity for one substrate and less activity for the other two substrates.

A lipolytic enzyme is considered to be a galactolipase if it has a higher activity on galactolipids than on phospholipids and triglycerides. Similarly, it is considered to  
25 be a phospholipase or a triacylglycerol lipase if it has a higher activity for that substrate than for the other two. The comparison may be done, e.g., by the plate assay in this specification using the three substrates; the largest clearing zone indicating the predominant activity.

The enzyme combination may comprise three or more lipolytic enzymes, e.g.  
30 comprising a galactolipase, a phospholipase and a triacylglycerol lipase.

The enzyme combination may have low activity on partially hydrolyzed lipids such as digalactosyl monoglyceride (DGMG), lysophospholipids (LPL) and mono- and diglycerides (MG, DG). Favorably, this may lead to accumulation of such partially hydrolyzed lipids in the dough and may improve the properties of the dough and/or the  
35 baked product.

#### Sources of lipolytic enzymes

The lipolytic enzymes may be prokaryotic, particularly bacterial, e.g. from *Pseudomonas* or *Bacillus*. Alternatively, the lipolytic enzymes may be eukaryotic, e.g.

from fungal or animal sources. Fungal lipolytic enzymes may be derived, e.g. from the following genera or species: *Thermomyces*, particularly *T. lanuginosus* (also known as *Humicola lanuginosa*); *Humicola*, particularly *H. insolens*; *Fusarium*, particularly *F. oxysporum*, *F. solani*, and *F. heterosporum*; *Aspergillus*, particularly *A. tubigensis*, *A. niger*, and *A. oryzae*; *Rhizomucor*; *Candida*, particularly *C. antarctica*; *Penicillium*, particularly *P. camembertii*; *Rhizopus*, particularly *Rhizopus oryzae*; or *Absidia*.

Some particular examples of lipolytic enzymes follow:

- Phospholipase from bee or snake venom or from mammal pancreas, e.g. porcine pancreas.
- 10     ▪ Phospholipase of microbial origin, e.g. from filamentous fungi, yeast or bacteria, such as the genus or species *Aspergillus*, *A. niger*, *Dictyostelium*, *D. discoideum*, *Mucor*, *M. javanicus*, *M. mucedo*, *M. subtilissimus*, *Neurospora*, *N. crassa*, *Rhizomucor*, *R. pusillus*, *Rhizopus*, *R. arrhizus*, *R. japonicus*, *R. stolonifer*, *Sclerotinia*, *S. libertiana*, *Trichophyton*, *T. rubrum*, *Whetzelinia*, *W. sclerotiorum*, *Bacillus*, *B. megaterium*, *B. subtilis*, *Citrobacter*, *C. freundii*, *Enterobacter*, *E. aerogenes*, *E. cloacae* *Edwardsiella*, *E. tarda*, *Erwinia*, *E. herbicola*, *Escherichia*, *E. coli*, *Klebsiella*, *K. pneumoniae*, *Proteus*, *P. vulgaris*, *Providencia*, *P. stuartii*, *Salmonella*, *S. typhimurium*, *Serratia*, *S. liquefaciens*, *S. marcescens*, *Shigella*, *S. flexneri*, *Streptomyces*, *S. violeceoruber*, *Yersinia*, or *Y. enterocolitica*.
- 20     ▪ Lipase from *Thermomyces lanuginosus* (*Humicola lanuginosa*) (EP 305216, US 5869438).
  - Lipase/phospholipase from *Fusarium oxysporum* (WO 98/26057.).
  - Lysophospholipases from *Aspergillus niger* and *A. oryzae* (WO 0127251).
  - Phospholipase A1 from *Aspergillus oryzae* (EP 575133, JP-A 10-155493).
  - 25     ▪ Lysophospholipase from *F. venenatum* (WO 00/28044).
  - Phospholipase B from *A. oryzae* (US 6146869).
  - Lipase from *A. tubigensis* (WO 9845453).
  - Lipase from *F. solani* (US 5990069).
  - Lipolytic enzyme from *F. culmorum* (US 5830736).
  - 30     ▪ Phospholipase from *Hyphozyma* (US 6127137).
  - Lipolytic enzymes described in PCT/DK 01/00448.
  - Lipolytic enzymes described in DK PA 2001 00304.
  - A variant obtained by altering the amino acid sequence a lipolytic enzyme, e.g. one of the above, e.g. as described in WO 2000/32758, particularly Examples 4, 5, 35 6 and 13, such as variants of lipase from *Thermomyces lanuginosus* (also called *Humicola lanuginosa*).

The lipolytic enzymes may have a temperature optimum in the range of 30-90°C, e.g. 30-70°C.

**Synergistic effect**

The combination of the two lipolytic enzymes has a synergistic effect on dough made with the combination or on a baked product made from the dough, particularly improved dough stabilization, i.e. a larger loaf volume of the baked product  
5 and/or a better shape retention during baking, particularly in a stressed system, e.g. in the case of over-proofing or over-mixing.

Additionally or alternatively, the synergistic effect on the baked product may include a lower initial firmness and/or a more uniform and fine crumb, improved crumb structure (finer crumb, thinner cell walls, more rounded cells), of the baked product,  
10 Additionally or alternatively, there may be a synergistic effect on dough properties, e.g. a less soft dough, higher elasticity, lower extensibility.

Synergy may be determined by making doughs or baked products with addition of the first and the second lipolytic enzyme separately and in combination, and comparing the effects; synergy is indicated when the combination produces a better  
15 effect than each enzyme used separately.

The comparison may be made between the combination and each enzyme alone at double dosage (on the basis of enzyme protein or enzyme activity). Thus, synergy may be said to occur if the effect of 0.5 mg of enzyme A + 1.0 mg of enzyme B is greater than the effect with 1.0 mg of enzyme A and also greater than the effect with  
20 2.0 mg of enzyme B.

Alternatively, the comparison may be made with equal total enzyme dosages (as pure enzyme protein). If the effect with the combination is greater than with either enzyme alone, this may be taken as an indication of synergy. As an example, synergy may be said to occur if the effect of 0.5 mg of enzyme A + 1.0 mg of enzyme B is  
25 greater than with 1.5 mg of enzyme A or B alone.

Suitable dosages for the enzymes may typically be found in the range 0.01-10 mg of enzyme protein per kg of flour, particularly 0.1-5 mg/kg, e.g. 0.2-1 mg/kg. Suitable dosages for each of the two enzymes in the combination may be found by first determining a suitable dosage for each enzyme alone (e.g. the optimum dosage, i.e.  
30 the dosage producing the greatest effect) and using 30-67 % (e.g. 33-50 %, particularly 50 %) of that dosage for each enzyme in the combination. Again, if the effect with the combination is greater than with either enzyme used separately, this is taken as an indication of synergy.

A lipolytic enzyme with phospholipase activity may be used at a dosage of  
35 200-5000 LEU/kg of flour, e.g. 500-2000 LEU/kg. The LEU activity unit is described in WO 99/53769.

A lipolytic enzyme with triacylglycerol lipase activity may be used at a dosage of 20-1000 LU/kg of flour, particularly 50-500 LU/kg. The LU method is described in WO 2000/32758.

#### Additional enzyme

5        Optionally, an additional enzyme may be used together with the lipolytic enzymes. The additional enzyme may be an amylase, particularly an anti-staling amylase, an amyloglucosidase, a cyclodextrin glucanotransferase, or the additional enzyme may be a peptidase, in particular an exopeptidase, a transglutaminase, a cellulase, a hemicellulase, in particular a pentosanase such as xylanase, a protease, a  
10 protein disulfide isomerase, e.g., a protein disulfide isomerase as disclosed in WO 95/00636, a glycosyltransferase, a branching enzyme (1,4- $\alpha$ -glucan branching enzyme), a 4- $\alpha$ -glucanotransferase (dextrin glycosyltransferase) or an oxidoreductase, e.g., a peroxidase, a laccase, a glucose oxidase, a pyranose oxidase, a lipoxygenase, an L-amino acid oxidase or a carbohydrate oxidase.

15        The additional enzyme may be of any origin, including mammalian and plant, and preferably of microbial (bacterial, yeast or fungal) origin and may be obtained by techniques conventionally used in the art.

      The amylase may be a fungal or bacterial alpha-amylase, e.g. from *Bacillus*, particularly *B. licheniformis* or *B. amyloliquefaciens*, or from *Aspergillus*, particularly *A. oryzae*, a beta-amylase, e.g. from plant (e.g. soy bean) or from microbial sources (e.g. *Bacillus*).

      The xylanase is preferably of microbial origin, e.g. derived from a bacterium or fungus, such as a strain of *Aspergillus*, in particular of *A. aculeatus*, *A. niger* (cf. WO 91/19782), *A. awamori* (WO 91/18977), or *A. tubigensis* (WO 92/01793), from a strain of  
25 *Trichoderma*, e.g. *T. reesei*, or from a strain of *Humicola*, e.g. *H. insolens* (WO 92/17573).

      The amyloglucosidase may be from *Aspergillus*, particularly *A. oryzae*.

      The glucose oxidase may be a fungal glucose oxidase, particularly from *Aspergillus niger*.

30        The protease may be a neutral protease from *Bacillus amyloliquefaciens*.

#### Anti-staling amylase

      The method or the composition of the invention may include addition of an anti-staling amylase. In particular, a galactolipase and a phospholipase may be used together with an anti-staling amylase, as described in WO 99/53769. The anti-staling  
35 amylase is an amylase that is effective in retarding the staling (crumb firming) of baked products, particularly a maltogenic alpha-amylase, e.g. from *Bacillus stearothermophilus* strain NCIB 11837.

Alternatively, the method or composition of the invention may be made without addition of an anti-staling amylase. In particular, a lipase and a phospholipase may be used without addition of an anti-staling amylase or without addition of a maltogenic alpha-amylase.

## 5 Composition comprising lipolytic enzymes

The present invention provides a composition comprising a combination of two lipolytic enzymes as described above. The composition may be an enzyme preparation for use as a baking additive. The composition may also comprise flour and may be a dough or a premix.

## 10 Enzyme preparation

The composition may be an enzyme preparation comprising a combination of lipolytic enzymes, for use as a baking additive in the process of the invention. The enzyme preparation may particularly be in the form of a granulate or agglomerated powder, e.g. with a narrow particle size distribution with more than 95 % (by weight) of  
15 the particles in the range from 25 to 500  $\mu\text{m}$ .

Granulates and agglomerated powders may be prepared by conventional methods, e.g. by spraying the enzymes onto a carrier in a fluid-bed granulator. The carrier may consist of particulate cores having a suitable particle size. The carrier may be soluble or insoluble, e.g. a salt (such as NaCl or sodium sulfate), a sugar (such as  
20 sucrose or lactose), a sugar alcohol (such as sorbitol), starch, rice, corn grits, or soy.

The enzyme preparation may also be supplied as a liquid formulation, particularly a stabilized liquid. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods.

## 25 Dough

The dough of the invention generally comprises wheat meal or wheat flour and/or other types of meal, flour or starch such as corn flour, corn starch, rye meal, rye flour, oat flour, oat meal, soy flour, sorghum meal, sorghum flour, potato meal, potato  
flour or potato starch.

30 The dough of the invention may be fresh, frozen or par-baked.

The dough of the invention is normally a leavened dough or a dough to be subjected to leavening. The dough may be leavened in various ways, such as by adding chemical leavening agents, e.g., sodium bicarbonate or by adding a leaven (fermenting dough), but it is preferred to leaven the dough by adding a suitable yeast  
35 culture, such as a culture of *Saccharomyces cerevisiae* (baker's yeast), e.g. a commercially available strain of *S. cerevisiae*.

The dough may also comprise other conventional dough ingredients, e.g.: proteins, such as milk powder, gluten, and soy; eggs (either whole eggs, egg yolks or egg whites); an oxidant such as ascorbic acid, potassium bromate, potassium iodate, azodicarbonamide (ADA) or ammonium persulfate; an amino acid such as L-cysteine;  
5 a sugar; a salt such as sodium chloride, calcium acetate, sodium sulfate or calcium sulfate.

The dough may comprise fat (triglyceride) such as granulated fat or shortening, but the invention is particularly applicable to a dough where less than 1 % by weight of fat (triglyceride) is added, and particularly to a dough which is made without addition of  
10 fat.

The dough may further comprise an emulsifier such as mono- or diglycerides, diacetyl tartaric acid esters of mono- or diglycerides, sugar esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, polyoxyethylene stearates, or lysolecithin.

#### 15 Pre-mix

The invention also provides a pre-mix comprising flour together with two lipolytic enzymes as described above. The pre-mix may contain other dough-improving and/or bread-improving additives, e.g. any of the additives, including enzymes, mentioned above.

## 20 MATERIALS AND METHODS

### Enzyme activity assays

#### Phospholipase activity (PHLU)

Phospholipase activity is measured as the release of free fatty acids from lecithin. 500  $\mu$ l 4% L-alpha-phosphatidylcholine (plant lecithin from Avanti), 5 mM  
25  $\text{CaCl}_2$  in 50 mM NaOAc, pH 5 is added to 50  $\mu$ l enzyme solution diluted to an appropriate concentration in water. The samples are incubated for 10 min at 30 °C and the reaction stopped at 95 °C for 5 min prior to centrifugation (5 min at 7000 rpm). Free fatty acids are determined using the NEFA C kit from Wako Chemicals GmbH; 25  $\mu$ l reaction mixture is added 250  $\mu$ l Reagent A and incubated 10 min at 37 °C. Then 500  
30  $\mu$ l Reagent B is added and the sample is incubated again, 10 min at 37 °C. The absorption is measured at 550 nm. Substrate and enzyme blinds (preheated enzyme samples (10 min at 95 °C) + substrate) are included. Oleic acid is used as a fatty acid standard. 1 PHLU equals the amount of enzyme capable of releasing 1  $\mu$ mol of free fatty acid/min at these conditions.



Plate assay for phospholipase activity

A) 50 ml 2% agarose in purified water is melted/stirred for 5 minutes and cooled to 60 - 63°C.

B) 50 ml 2% plant L-alpha-Phosphatidylcholine 95% in 0,2M NaOAc, 10 mM  
5 CaCl<sub>2</sub>, pH 5,5 at 60°C in 30 min. is blended in 15 sec. with ultrathorax.

Equal volumes of 2% agarose and 2% Lecithin (A and B) are mixed. 250 µl 4 mg/ml crystal violet in purified water is added as indicator. The mixture is poured into appropriate petri dishes (e.g. 30 ml in 14cm Ø dish), and appropriate holes are made in the agar (3-5 mm) for application of enzyme solution.

10 The enzyme sample is diluted to a concentration corresponding to OD<sub>280</sub> = 0.5 and 10 microliter is applied into holes in the agarose/lecithin-matrix. Plates are incubated at 30°C and reaction zones in the plates are identified after 20-24 hours incubation, and the size of the clearing zone indicates the phospholipase activity.

Plate assays for galactolipase and triacylglycerol lipase activity

15 Plate assays are carried out as for the phospholipase assay, except that digalactosyl diglyceride (DGDG) or olive oil is used instead of L-alpha-Phosphatidylcholine.

**Baking methods**Sponge dough

20 A liquid sponge is prepared by mixing 34.8 parts of water, 60 parts of flour and 1.5 parts of instant yeast, and fermenting for 3 hours at 24°C. A dough is then prepared by mixing the liquid sponge with 22.93 parts of water, 40 parts of flour, 0.5 part of instant yeast, 11.26 parts of 42 high-fructose corn syrup, 0.25 part of calcium propionate, 2 parts of oil and 2 parts of salt, 50 ppm of ascorbic acid 50 parts of wheat  
25 flour, 0.5 part of SSL (sodium stearoyl-2-lactylate), 2 parts of salt, 6 parts of sugar and water and ascorbic acid as required.

European straight dough procedure

A dough is prepared by mixing 100 parts (by weight) of wheat flour, 4 parts of yeast, 1.5 parts of salt and 1.5 parts of sugar with water and ascorbic acid as required  
30 to reach a suitable dough consistency.

Shape factor (shape retention)

The shape factor is taken as the ratio between the height and diameter of rolls after baking (average of 10 rolls). A higher value indicates a better shape retention.

### Dough softness

Softness is a measure of the degree to which, or ease with which, a dough will compress or resist compression. A sensory evaluation is done by a trained and skilled baker feeling and squeezing the dough. The results are expressed on a scale from 0 (little softness) to 10 (very soft) with the control (dough without enzyme addition) taken as 5.

### Dough extensibility

Extensibility is a measure of the degree by which a dough can be stretched without tearing. A sensory evaluation is done by a trained and skilled baker pulling a piece of kneaded dough (about 30 g) and judging the extensibility. The results are expressed on a scale from 0 (Short /low extensibility) to 10 (long /high extensibility) with the control (dough without enzyme addition) taken as 5.

### Dough elasticity

Elasticity is a measure of the degree to which a dough tends to recover its original shape after release from a deforming force. It is evaluated by rolling a piece of dough (about 30 g) to a size of about 10 cm, and having a trained and skilled baker carefully pulling at opposite ends to judge the resistance and elasticity. The results are expressed on a scale from 0 (low/weak elasticity/recovery) to 10 (high/strong elasticity/recovery) with the control (dough without enzyme addition) taken as 5.

## 20 EXAMPLES

### **Example 1: Synergistic effect of phospholipase and galactolipase on dough stabilization**

Lipolytic enzyme combinations were tested in a European Straight dough procedure as described above. Fungal alpha-amylase (Fungamyl Super MA, 40 ppm) and an oxidation system (ascorbic acid, 30 ppm) were added to the dough system. Each dough was split into rolls and pan bread. Over-proofing (indicating a stressed system) was carried out for the rolls (70 min.) and the pan bread (80 min.).

Combinations with the following lipolytic enzymes were tested: Variant 39 was tested in combination with variant 91 or with *Aspergillus oryzae* phospholipase. Variants 39 and 91 are variants of the *Thermomyces lanuginosus* lipase according to WO 2000/32758.

The combination of variants 91 and 39 was selected because of the high phospholipase activity and the high galactolipase activity, respectively. The *Aspergillus oryzae* phospholipase and variant 39 combination were chosen due to the combination of a pure phospholipase and an enzyme with high DGDG activity. The plate assays

described above showed that each enzyme was specific with little or no activity for the two other substrates.

The lipolytic enzymes were added according to the table below. The tests with a single enzyme were conducted with a dosage found to be optimum for the enzyme in question, and combinations were tested as indicated, with each enzyme at 33, 50 or 67 % of optimal dosage.

| Lipolytic enzyme                            | Rolls                  |              | Pan bread              |
|---|------------------------|--------------|------------------------|
|   | Specific volume (ml/g) | Shape factor | Specific volume (ml/g) |
| <b>Variant 91 (20 LU/kg)</b>                | 7.52                   | 0.66         | 5.75                   |
| <b>Variant 39 (250 LU/kg)</b>               | 7.42                   | 0.65         | 5.77                   |
| <b>Variant 91 (50 %) + variant 39 (33%)</b> | 7.57                   | 0.66         | 5.94                   |

The results demonstrate that the combination of Variant 91 with Variant 39, added at 50 % and 33 % respectively of optimal dosage, improves the specific volume for both the rolls and the pan bread compared to the each enzyme added separately at optimum dosage.

The results regarding volume and stability improvement from the combination of *Aspergillus oryzae* phospholipase with Variant 39 are listed in the table below.

15

| Lipolytic enzyme  | Rolls                  |              | Pan bread              |
|---|------------------------|--------------|------------------------|
|   | Specific volume (ml/g) | Shape factor | Specific volume (ml/g) |
| <b><i>A. oryzae</i> Phospholipase 0,1 mg/kg</b>                 | 6,27                   | 0,57         | 4,96                   |
| <b>Variant 39 (250 LU/kg)</b>                                   | 6,40                   | 0,60         | 5,18                   |
| <b><i>A. oryzae</i> Phospholipase (33 %) + variant 39 (67%)</b> | 7,31                   | 0,68         | 5,80                   |

The combination of *A. oryzae* Phospholipase and Variant 39 at 33 % and 67 %, respectively, of optimal dosage increases the specific volume considerably

compared to each enzyme added separately at optimum dosage. The combination also has a positive contribution to the shape factor of the rolls.

Both the results described above show that the combination of a phospholipase and a galactolipase improves the volume and stability (shape factor) of the rolls and bread, compared to the rolls and bread containing up to thrice the dosages of the enzymes added separately.

#### **Example 2: Synergistic effect of triacylglycerol lipase and phospholipase on dough stabilization**

A phospholipase A2 from porcine pancreas was tested in combination with a 1,3-specific triacylglycerol lipase from *Thermomyces lanuginosus* in the European straight dough procedure as described above. The results were compared to each enzyme used alone in dosages considered to be optimal. The enzyme combination was made with 50% of optimal dosage of each of the enzymes.

Each dough was split into rolls and pan bread. The rolls were proofed for 70 minutes (over proofing), and the pan bread was proofed for 80 minutes (over proofing). The over proofing was carried out to stress the system in order to test the stabilizing effect of the enzymes.

|  | Rolls          |              | Pan bread      |
|--|----------------|--------------|----------------|
|  | Sp. Vol (ml/g) | Shape factor | Sp. Vol (ml/g) |
| Phospholipase (3mg)                              | 6.24           | 0.56         | 5.60           |
| Triacylglycerol lipase (1000LU)                  | 6.43           | 0.58         | 5.43           |
| Phospholipase + triacylglycerol lipase (50%/50%) | 6.88           | 0.60         | 5.93           |

The two enzymes were found to be very specific, i.e. the triacylglycerol lipase has very little activity on phospholipid and galactolipids, and the phospholipase has very little activity on triglycerides and galactolipids.

The results show that when the phospholipase and the triacylglycerol lipase are combined they give a better volume and shape factor than each of the enzyme separately in a stressed system.

#### **Example 3: Synergistic effect on dough properties and loaf volume**

The combination of Lipase/phospholipase from *Fusarium oxysporum* (FoL) and Variant 6 on dough and bread was evaluated. Variant 6 is a variant of the

*Thermomyces lanuginosus* lipase with the following amino acid alterations (SPIRR indicates a peptide extension at the N-terminal, and 270AGGFS indicates a peptide extension at the C-terminal).

- Variant 6: SPIRR +G91A +D96W +E99K +G263Q +L264A +I265T +G266D  
5 +T267A +L269N +270AGGFS

Loaves were prepared according to the invention by adding Variant 6 (25 LU/kg flour) and FoL (500 LU/kg flour) to the dough. For comparison, loaves were baked without lipolytic enzymes, with FoL alone (1000 LU/kg) or Variant 6 alone (50 LU/kg) which were found to be the optimal dosages for the enzymes. The LU assay  
10 method is described in WO 2000/32758.

The standard sponge dough WPB formula was used as described above, with the hydrated distilled MG and SSL eliminated to avoid masking effects on the enzyme. Loaves contained 2% soy oil as well as fungal amylase and pentosanase (Fungamyl Super MA, 50 ppm). The oxidation system was 50 ppm ascorbic acid. In addition to  
15 subjective evaluations, crumb softness and elasticity were measured 24 hours after baking. The trial was repeated once.

Dough evaluations. Evaluations of the dough at the sheeter are shown below. The dough scores for the two trials were identical.

| Lipolytic enzyme | None | FoL | Variant 6 | FoL + Variant 6 |
|------------------|------|-----|-----------|-----------------|
| Softness         | 5.5  | 4.5 | 4.5       | 4.0             |
| Extensibility    | 5.0  | 4.5 | 4.5       | 4.0             |
| Elasticity       | 5.0  | 5.5 | 5.5       | 6.0             |

20

The results show that the combination of FoL and Variant 6 yielded dough that was less soft, less extensible and more elastic than either enzyme alone at double dosage.

The specific volume data from the tested loaves are shown below.  
25 Reproducibility between the 2 days was high.

| Lipolytic enzyme         | None | FoL  | Variant 6 | FoL + Variant 6 |
|--------------------------|------|------|-----------|-----------------|
| Specific Volume, cc/gram | 6.0  | 6.15 | 6.15      | 6.3             |

The results demonstrate that the combination of two lipolytic enzymes gives a larger loaf volume than either enzyme alone at double dosage.

**Example 4: Synergistic effect on dough stabilization.**

Variant 32 was tested in combination with Variant 13 and Variant 60. The 5 variants are variants of the *Thermomyces lanuginosus* lipase with the following amino acid alterations (where SPIRR indicates a peptide extension at the N-terminal, and 270AGGFS indicates a peptide extension at the C-terminal):

- Variant 32: 91A +D96W +E99K +G263Q +L264A +I265T +G266D +T267A +L269N + 270AGGFS
- 10     ▪ Variant 60: G91A +D96W +E99K +G263Q +L264A +I265T +G266S +T267A +L269N + 270AGGFS
- Variant 13: D96F +G266S

Each combination was tested in a European straight dough procedure, as described above. The results were compared to each enzyme used alone. Lipolytic 15 enzymes were added as shown in the table below. The tests with a single enzyme were conducted with a dosage considered optimum for that enzyme, and the enzyme combinations were tested with each enzyme at 50 % of the optimum dosage. The combination of Variant 32 and Variant 13 was also tested with each enzyme at 40 % of the optimum dosage, i.e. 20 % lower dosage.

20     Each dough was split into rolls and pan bread. The rolls were proofed for 70 minutes (over proofing), and the pan bread was proofed for 80 minutes (over proofing). The over proofing was carried out to stress the system, in order to test the lipolytic enzymes as stabilizers.

The results from over-proofing are shown below:

25

| Lipolytic enzyme added     | Rolls           |              | Pan bread       |
|----------------------------|-----------------|--------------|-----------------|
|                            | Sp. Vol. (ml/g) | Shape factor | Sp. Vol. (ml/g) |
|                            | 70 min          | 70 min       | 80 min          |
| Variant 32 (200LU)         | 7.78            | 0.67         | 6.16            |
| Variant 13 (500LU)         | 7.24            | 0.66         | 5.69            |
| Variant 60 (100LU)         | 7.02            | 0.67         | 5.69            |
| Variant 32+Variant 13, 50% | 8.26            | 0.71         | 6.24            |

14

|                                       |      |      |      |
|---------------------------------------|------|------|------|
| <b>Variant 32+Variant 13,<br/>40%</b> | 8.03 | 0.69 | 6.30 |
| <b>Variant 32+Variant 60,<br/>50%</b> | 7.87 | 0.69 | 6.39 |

The results show that when the bread is stressed (over-proofed), the combinations of Variant 32 with Variant 13 or Variant 60 clearly give an improved volume and shape compared to each enzyme used alone, particularly Variant 32 +  
5 Variant 13, even at reduced dosage. The results reveal that when bread is stressed (over proofed), the combinations show a significantly improved effect on volume and shape factor.

Furthermore, it was observed that the combination of Variant 32 and Variant 13 at 40 % of optimum dosage provided a more uniform and fine crumb compared to  
10 each enzyme used alone.

**CLAIMS**

1. A method for increasing the loaf volume or improving the shape retention of a baked product made from dough, comprising adding to the dough:
  - a) a phospholipase and a galactolipase, or
  - 5 b) a phospholipase and a triacylglycerol lipase, or
  - c) a galactolipase and a triacylglycerol lipase.
2. A method of preparing a dough or a baked product made from dough, comprising adding to the dough:
  - a) a galactolipase and
  - 10 b) a phospholipase or a triacylglycerol lipase.
3. A method of preparing a dough or a baked product made from dough, comprising adding to the dough a combination of two lipolytic enzymes wherein the combination produces a synergistic effect on the loaf volume or shape retention of the baked product.
- 15 4. The method of the preceding claim wherein the two lipolytic enzymes are :
  - a) a phospholipase and a galactolipase, or
  - b) a phospholipase and a triacylglycerol lipase, or
  - c) a galactolipase and a triacylglycerol lipase.
5. A method of preparing a dough or a baked product made from dough, which  
20 comprises adding to the dough:
  - a) a phospholipase and a galactolipase, or
  - b) a phospholipase and a triacylglycerol lipase, or
  - c) a galactolipase and a triacylglycerol lipaseand which does not comprise adding a maltogenic alpha-amylase to the dough.
- 25 6. A composition comprising:
  - a) a galactolipase and
  - b) a phospholipase or a triacylglycerol lipase.
7. A composition comprising a combination of two lipolytic enzymes wherein the combination produces a synergistic effect on the loaf volume or shape retention of a  
30 baked product made from dough including the composition.



8. The composition of the preceding claim wherein the two lipolytic enzymes are:
- a) a phospholipase and a galactolipase, or
  - b) a phospholipase and a triacylglycerol lipase, or
  - 5 c) a galactolipase and a triacylglycerol lipase.
9. A composition which comprises.
- a) a phospholipase and a galactolipase, or
  - b) a phospholipase and a triacylglycerol lipase, or
  - c) a galactolipase and a triacylglycerol lipase,
- 10 and which does not comprise a maltogenic alpha-amylase.
10. The composition of any preceding claim which comprises flour, particularly a dough or a premix.
11. A method of preparing a dough or a baked product made from dough, comprising:
- 15 a) determining substrate specificities of at least two lipolytic enzymes,
  - b) selecting two lipolytic enzymes which are:
    - i) a phospholipase and a galactolipase, or
    - ii) a phospholipase and a triacylglycerol lipase, or
    - iii) a galactolipase and a triacylglycerol lipase.
  - 20 c) for each enzyme, determining an effective dosage in the dough to increase the loaf volume or improve the shape retention of a baked product made from the dough,
  - d) adding to the dough a combination of the first and the second lipolytic enzyme wherein each enzyme is added in an amount of 33-67 of the effective
  - 25 dosage.
12. A method for producing a lipolytic enzyme preparation, comprising:
- a) determining the substrate specificities of at least two lipolytic enzymes,
  - b) selecting two lipolytic enzymes which are:
    - i) a phospholipase and a galactolipase, or
    - 30 ii) a phospholipase and a triacylglycerol lipase, or
    - iii) a galactolipase and a triacylglycerol lipase.
  - c) making baked products from doughs with addition of the two lipolytic enzymes separately and in combination,
  - d) determining the loaf volumes or the shape retention of the baked products,

- e) selecting two lipolytic enzymes having a synergistic effect, and
- f) producing the enzyme preparation comprising a combination of the two lipolytic enzymes.

13. A method of preparing a dough or a baked product made from dough,  
5 comprising:

- a) selecting two lipolytic enzymes,
- b) for each enzyme, determining an effective dosage in the dough to increase the loaf volume or improve the shape retention of a baked product made from the dough,
- 10 c) adding to the dough a combination of the first and the second lipolytic enzyme wherein each enzyme is added in an amount of 33-67 % of the effective dosage.

14. The method of the preceding claim wherein the two lipolytic enzymes are:

- a) a phospholipase and a galactolipase, or
- 15 b) a phospholipase and a triacylglycerol lipase, or
- c) a galactolipase and a triacylglycerol lipase.

## INTERNATIONAL SEARCH REPORT

Inter national Application No  
PCT7DK 01/00472

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC 7 A21D8/04 A23L1/03   |   |  |
|---|---|--|
| According to International Patent Classification (IPC) or to both national classification and IPC   |   |  |
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>IPC 7 A21D A23L C12N C12P   |   |  |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched   |   |  |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used)<br>WPI Data, EPO-Internal, PAJ, FSTA   |   |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |   |  |
| Category *  | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.                              |
| X   | WO 00 28044 A (NOVO NORDISK BIOINDUSTRY LTD ;NOVO NORDISK BIOTECH INC (US))<br>18 May 2000 (2000-05-18)<br>cited in the application<br>page 40, line 18 -page 44, line 27<br>claims 1,40-44 | 1,3-5,<br>7-11,13,<br>14                           |
| X   | EP 0 869 167 A (NOVONORDISK AS)<br>7 October 1998 (1998-10-07)<br>cited in the application<br>page 21, line 11-37<br>examples 20,21<br>claims 65,66   | 1,3-5,<br>7-11,13,<br>14                           |
| -/--  |   |  |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.   |   |  |
| * Special categories of cited documents :<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"E" earlier document but published on or after the international filing date<br>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed<br>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.<br>"&" document member of the same patent family |   |  |
| Date of the actual completion of the international search   |   | Date of mailing of the international search report |
| 17 October 2001   |   | 25/10/2001   |
| Name and mailing address of the ISA<br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax: (+31-70) 340-3016  |   | Authorized officer<br>Piret-Viprey, E              |

## INTERNATIONAL SEARCH REPORT

Inter. Application No  
PCT7DK 01/00472

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.         |
|------------|---|-------------------------------|
| X          | WO 99 53769 A (NOVONORDISK AS)<br>28 October 1999 (1999-10-28)<br>cited in the application<br>page 2, line 29 -page 3, line 20<br>page 4, line 26 -page 5, line 35<br>claims 1,6,11 | 1,3,4,7,<br>8,10,11,<br>13,14 |
| X          | US 5 989 599 A (TRAITLER HELMUT ET AL)<br>23 November 1999 (1999-11-23)<br>column 2, line 57 -column 3, line 4<br>claims 1,2,3,68,9,10,12,15  | 7-9                           |
| X          | US 3 652 397 A (PARDUN HERMANN)<br>28 March 1972 (1972-03-28)<br>column 1, line 25-39,69-75<br>claim 1  | 7-9                           |
| P,X        | US 6 146 869 A (HARRIS PAUL ET AL)<br>14 November 2000 (2000-11-14)<br>cited in the application<br>column 24, line 53-65<br>column 26, line 36-49<br>column 27-28                   | 1,3-5,<br>7-14                |
| P,X        | EP 1 108 360 A (DANISCO)<br>20 June 2001 (2001-06-20)<br><br>page 5, line 27-41<br>page 6, line 3-14<br>claims 1,17-19,28,29,31-34  | 1,3,4,<br>6-11,13,<br>14      |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC17DK 01/00472

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---|---------------------|--|--|
| WO 0028044                                | A | 18-05-2000          | AU 2148400 A<br>EP 1131444 A1<br>WO 0028044 A1   | 29-05-2000<br>12-09-2001<br>18-05-2000   |
| EP 0869167                                | A | 07-10-1998          | AU 5187898 A<br>CN 1245532 A<br>WO 9826057 A1<br>EP 0869167 A2<br>JP 2000507458 T<br>US 6143545 A<br>US 6103505 A<br>EP 0884524 A2   | 03-07-1998<br>23-02-2000<br>18-06-1998<br>07-10-1998<br>20-06-2000<br>07-11-2000<br>15-08-2000<br>16-12-1998   |
| WO 9953769                                | A | 28-10-1999          | AU 3025399 A<br>WO 9953769 A1<br>EP 1073339 A1   | 08-11-1999<br>28-10-1999<br>07-02-2001   |
| US 5989599                                | A | 23-11-1999          | AT 197610 T<br>AU 713557 B2<br>AU 5087896 A<br>BR 9602023 A<br>CA 2174793 A1<br>CN 1141343 A<br>DE 69610939 D1<br>DE 69610939 T2<br>DK 739985 T3<br>EP 0739985 A2<br>ES 2153072 T3<br>HU 9601058 A2<br>IL 118001 A<br>JP 8291188 A<br>NO 961615 A<br>NZ 286423 A<br>PT 739985 T<br>TR 960961 A2<br>TW 430668 B | 15-12-2000<br>02-12-1999<br>07-11-1996<br>07-04-1998<br>25-10-1996<br>29-01-1997<br>21-12-2000<br>22-03-2001<br>02-01-2001<br>30-10-1996<br>16-02-2001<br>30-12-1996<br>13-08-2000<br>05-11-1996<br>25-10-1996<br>19-12-1997<br>30-03-2001<br>21-11-1996<br>21-04-2001 |
| US 3652397                                | A | 28-03-1972          | DE 1900959 A1<br>AT 306495 B<br>BE 744202 A1<br>DK 139861 B<br>FR 2028016 A5<br>GB 1285644 A<br>NL 7000322 A , B   | 27-08-1970<br>15-02-1973<br>08-07-1970<br>07-05-1979<br>02-10-1970<br>16-08-1972<br>13-07-1970   |
| US 6146869                                | A | 14-11-2000          | AU 1222901 A<br>WO 0129222 A2  | 30-04-2001<br>26-04-2001   |
| EP 1108360                                | A | 20-06-2001          | AU 1723801 A<br>EP 1108360 A1<br>GB 2358784 A<br>WO 0139602 A1   | 12-06-2001<br>20-06-2001<br>08-08-2001<br>07-06-2001   |